Shopping Cart
Remove All
Your shopping cart is currently empty
Ontorpacept
Copy Product Info
😃Good
Catalog No. T81605Cas No. 2131089-46-6
Alias TTI-621
Ontorpacept (TTI-621) is a soluble fusion protein comprising the N-terminal (1-118) of human SIRPα fused to the Fc region of human IgG1. This N-terminal (1-118) segment serves as the binding domain for CD47, an inhibitor of macrophage-mediated phagocytosis. As a checkpoint inhibitor that blocks CD47, ontorpacept exhibits antitumor activity [1].
Ontorpacept
Ontorpacept
Copy Product Info😃Good
Catalog No. T81605Alias TTI-621Cas No. 2131089-46-6
Ontorpacept (TTI-621) is a soluble fusion protein comprising the N-terminal (1-118) of human SIRPα fused to the Fc region of human IgG1. This N-terminal (1-118) segment serves as the binding domain for CD47, an inhibitor of macrophage-mediated phagocytosis. As a checkpoint inhibitor that blocks CD47, ontorpacept exhibits antitumor activity [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Ontorpacept (TTI-621) is a soluble fusion protein comprising the N-terminal (1-118) of human SIRPα fused to the Fc region of human IgG1. This N-terminal (1-118) segment serves as the binding domain for CD47, an inhibitor of macrophage-mediated phagocytosis. As a checkpoint inhibitor that blocks CD47, ontorpacept exhibits antitumor activity [1]. |
| In vitro | Ontorpacept, at concentrations ranging from 0.001 to 1000 nmol/L administered over 2 hours, dose-dependently enhances macrophage phagocytosis of tumor cells in samples from patients with acute myeloid leukemia, myelodysplastic syndromes, multiple myeloma, B-cell acute lymphoblastic leukemia, and T-cell acute lymphoblastic leukemia, with an average EC50 of 10 nmol/L [1]. |
| In vivo | Ontorpacept, at a dose of 8 mg/kg administered intraperitoneally thrice weekly for four weeks, demonstrated antitumor activity in an acute myeloid leukemia xenograft model in SCID mice [1]. |
| Synonyms | TTI-621 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD47 |
| Cas No. | 2131089-46-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Ontorpacept | purchase Ontorpacept | Ontorpacept cost | order Ontorpacept | Ontorpacept in vivo | Ontorpacept in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.